Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Table 4 Difference of co-existence of T790M mutation between patients with EGFR 19 del and L858R mutation

Patient	Exon 19 deletion	Exon 21 L858R mutation	P value^a
Patient	(n = 140)	(n = 82)	P value^a
T790M mutation pre-TKI			0.554
Positive	3 (5.6)	3 (8.8)	0.554
Negative	51 (94.4)	31 (91.2)
T790M mutation post-TKI			0.176
Positive	21 (24.4)	17 (35.4)	0.176
Negative	65 (75.6)	31 (64.6)

^aBy using χ² test. All values are presented as the number of patients followed by the percentage in the parentheses

ISSN: 2523-3548